Results 101 to 110 of about 840,777 (236)

No pills for poor people? Understanding the disembowelment of India’s patent regime [PDF]

, 2005
The recent amendment to the Patent Act, 1970 brings India into full compliance with its obligations under the TRIPs Agreement, in particular allowing for product patents in the area of pharmaceuticals and agrichemicals.
Rangnekar, Dwijen
core  

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

External technology sourcing: The effect of uncertainty on governance mode choice [PDF]

This study examines the effect of external and relational uncertainty on the governance choice for inter-organizational technology sourcing. We develop a number of hypotheses about the impact of environmental turbulence, technological newness ...
Duysters, Geert, Vanhaverbeke, Wim, Vrande, Vareska van de   +2 more
core  

Hip morphology‐based osteoarthritis risk prediction models: development and external validation using individual participant data from the World COACH Consortium

Arthritis Care &Research, Accepted Article.
Objectives This study aims to develop hip morphology‐based radiographic hip osteoarthritis (RHOA) risk prediction models and investigates the added predictive value of hip morphology measurements and the generalizability to different populations. Methods We combined data from nine prospective cohort studies participating in the World COACH consortium ...
Myrthe A. van den Berg, Fleur Boel, Michiel M.A. van Buuren, Noortje S. Riedstra, Jinchi Tang, Harbeer Ahedi, Nigel K. Arden, Sita M.A. Bierma‐Zeinstra, Cindy G. Boer, Flavia M. Cicuttini, Timothy F. Cootes, David T. Felson, Willem Paul Gielis, Joshua Heerey, Graeme Jones, Stefan Kluzek, Nancy E. Lane, Claudia Lindner, Joyce B.J. van Meurs, Andrea Mosler, Amanda E. Nelson, Michael C. Nevitt, Edwin H. Oei, Jos Runhaar, Harrie Weinans, Jesse H. Krijthe, Rintje Agricola   +26 more
wiley   +1 more source

Potential means of support for materials processing in space. A history of government support for new technology [PDF]

Development of a given technology for national defense and large systems developments when the task is too large or risky for entrepreneurs, yet is clearly in the best interest of the nation are discussed.
Mckannan, E. C.
core   +1 more source

Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment

Arthritis Care &Research, Accepted Article.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histological features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H Weisman, Philip M Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L Barnas, David Wofsy, Diane Kamen, Richard A Furie, Deepak A Rao, the Accelerating Medicines Partnership (AMP) RA/SLE Network, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +26 more
wiley   +1 more source

Technology transfer by new ventures within the chemical and pharmaceutical industry

, 2013
The role of new ventures for technology transfer from universities and research institutions to companies and between companies focused on the chemical and pharmaceutical industry are discussed in this article.
Festel, G. (Gunter)
core  

Influence of variability in starting materials quality on stability of finished drug products: a quality-by-design factor and response [PDF]

, 2012
The use of ill selected excipients in drug formulations can have a significant influence on the overall stability. Therefore, evaluation of chemical and physical excipient compatibility with the API has become a major part in the development of new drug ...
Bauters, Tieneke, D'Hondt, Matthias, De Spiegeleer, Bart, Robays, Hugo, Vandenbroucke, Johan, Wynendaele, Evelien   +5 more
core   +1 more source

The impact of positive lifestyle behaviors on direct healthcare cost savings for low back pain

Arthritis Care &Research, Accepted Article.
Objective This study aimed to investigate the relationship between a previously purpose‐developed lifestyle behavior scale and healthcare cost savings related to low back pain (LBP). Methods This longitudinal study utilised data from the AUstralian Twin BACK (AUTBACK) study. LBP and lifestyle behavior measures were collected at baseline.
Ye Tian, Katharine E. Roberts, Michelle Hall, Paula R. Beckenkamp, Angelo Sabag, Karoline Moe, Ana Paula Carvalho‐e‐Silva, Emily J. Callander, Paulo H. Ferreira   +8 more
wiley   +1 more source

"Regulating Healthcare Technologies and Medical Supplies: A Comparative Overview" [PDF]

, 1995
A complex relationship exists among EU regulations, current national practices and rules, institutional capacities to implement regulatory adjustments and the legacy of past health and regulatory policy and traditions.
Altenstetter, Christa.
core